US Markets
Home›US Markets›IPOs›The FDA blocked Summit Therapeutics' lung-cancer drug
The FDA blocked Summit Therapeutics' lung-cancer drug
Summit Therapeutics' shares fell 10% following the rejection.
Summit Therapeutics faced a setback when the FDA declined to approve a lung-cancer drug, according to MarketWatch.
The regulator stated the medication must demonstrate its ability to extend patients' lives, adding pressure on the company.
Following the decision, the company's stock dropped sharply, reflecting investor uncertainty.
The market reaction underscores the drug's significance in oncology treatments.
← Newer storyNvidia expects another earnings report.Older story →Jensen Huang resigned as Nvidia CEO.
More like this
US MarketsNvidia expects another earnings report.
US Markets$5 billion investment in Anthropic IPO
US MarketsJensen Huang urged to return to Nvidia
US MarketsNvidia reports 91% revenue growth